Tetrahydro-β-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity

Eur J Med Chem. 2023 Nov 15:260:115776. doi: 10.1016/j.ejmech.2023.115776. Epub 2023 Aug 30.

Abstract

A series of tetrahydro-β-carboline (THβC)-based hydroxamic acids were rationally designed and synthesized as novel selective HDAC6 inhibitors (sHDAC6is) by the application of scaffold hopping strategy. Several THβC analogues were highly potent (IC50 < 5 nM) and selective against HDAC6 enzyme and exhibited good antiproliferative activity against human multiple myeloma (MM) cell. Molecular docking interpreted the structure activity relationship (SAR). Target engagement of HDAC6 was confirmed in RPMI-8226 cells using the WB assay. In vitro, (1S, 3R)-1-(4-chlorophenyl)-N-(4-(hydroxycarbamoyl)benzyl)-2,3,4,9-tetrahydro-1H-pyrido[3, 4-b]indole-3-carboxamide (14g) showed potent broad antiproliferative activity against various tumors including leukemia, colon cancer, melanoma, and breast cancer cell lines, better than ACY-1215. Moreover, 14g also showed good pharmacokinetics properties in mice via oral administration.

Keywords: Antiproliferative; HDAC6 inhibitor; Selectivity; Synthesis; THβC.

MeSH terms

  • Administration, Oral
  • Animals
  • Carbolines* / pharmacology
  • Histone Deacetylase 6
  • Humans
  • Mice
  • Molecular Docking Simulation

Substances

  • Histone Deacetylase 6
  • tryptoline
  • Carbolines